Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib plus durvalumab and gemcitabine/cisplatin in first-line IDH1-mutated cholangiocarcinoma
jRCT2031240643Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ivosidenib in cholangiocarcinoma (CCA), sponsored by Servier. Primary endpoints: Dose-limiting toxicities in Safety Lead-in Phase, Dose modifications in Safety Lead-in Phase and 1 more. Started Oct 2025; status: active, not recruiting.
02
Drugs
ivosidenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on jRCT2031240643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240643.